These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2547677)

  • 1. Adventitious viral agents in biological products.
    Minor P
    Dev Biol Stand; 1989; 70():173-9. PubMed ID: 2547677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of biological products prepared from mammalian cell culture. Detecting viruses in cell banks.
    Dev Biol Stand; 1998; 93():129. PubMed ID: 9737388
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety of biological products prepared from mammalian cell culture. Bovine spongiform encephalopathy and other non-viral transmissible agents.
    Dev Biol Stand; 1998; 93():133-4. PubMed ID: 9737391
    [No Abstract]   [Full Text] [Related]  

  • 4. Viral safety of biological products and the concept of validation.
    Horaud F
    Dev Biol Stand; 1996; 88():19-24. PubMed ID: 9119135
    [No Abstract]   [Full Text] [Related]  

  • 5. An overview of animal cell substrates for biological products.
    Petricciani J; Sheets R
    Biologicals; 2008 Nov; 36(6):359-62. PubMed ID: 18674929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimum safety requirements for preclinical testing.
    Dorner F; Barrett PN; Schwartz HP; Eibl H
    Dev Biol Stand; 1993; 81():245-52. PubMed ID: 8174809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bovine sera used in the manufacture of biologicals: current concerns and policies of the U.S. Food and Drug Administration regarding the transmissible spongiform encephalopathies.
    Asher DM
    Dev Biol Stand; 1999; 99():41-4. PubMed ID: 10404874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Process changes and their effect on process evaluation for viral clearance.
    Marcus-Sekura C
    Dev Biol Stand; 1996; 88():125-30. PubMed ID: 9119123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of biological products prepared from mammalian cell culture. In-process testing for viral agents.
    Dev Biol Stand; 1998; 93():130-1. PubMed ID: 9737389
    [No Abstract]   [Full Text] [Related]  

  • 10. [Viral safety concept: application to blood and blood products].
    Trouvin JH
    Rev Prat; 2005 Nov; 55(18):2033-8. PubMed ID: 16419908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Issues related to harmonization of testing requirements for viral safety.
    Hayakawa T
    Dev Biol Stand; 1996; 88():15-8. PubMed ID: 9119129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic evaluation of in vitro and in vivo adventitious virus assays for the detection of viral contamination of cell banks and biological products.
    Gombold J; Karakasidis S; Niksa P; Podczasy J; Neumann K; Richardson J; Sane N; Johnson-Leva R; Randolph V; Sadoff J; Minor P; Schmidt A; Duncan P; Sheets RL
    Vaccine; 2014 May; 32(24):2916-26. PubMed ID: 24681273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transmissible spongiform encephalopathy agents and animal sera.
    Dormont D
    Dev Biol Stand; 1999; 99():25-34. PubMed ID: 10404872
    [No Abstract]   [Full Text] [Related]  

  • 14. Removal of TSE agents from blood products.
    Foster PR
    Vox Sang; 2004 Jul; 87 Suppl 2():7-10. PubMed ID: 15209867
    [No Abstract]   [Full Text] [Related]  

  • 15. Current issues in viral assays and viral clearance evaluation.
    Lubiniecki AS
    Dev Biol Stand; 1996; 88():9-11. PubMed ID: 9119167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WHO requirements for the use of animal cells as in vitro substrates for the production of biologicals (requirements for biological substances No 50).
    Dev Biol Stand; 1998; 93():141-71. PubMed ID: 9737395
    [No Abstract]   [Full Text] [Related]  

  • 17. Industry perspective for biotech products.
    Möritz A
    Dev Biol (Basel); 2004; 118():37-44. PubMed ID: 15645671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ICH guidelines and PhEur monographs on derivation and characterisation of cell substrates used for production of biotechnological/biological products. International Conference on Harmonisation.
    Dobbelaer R
    Dev Biol Stand; 1999; 98():159-65; discussion 167. PubMed ID: 10494969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future directions for ensuring viral safety of biopharmaceuticals.
    Trent DW
    Dev Biol Stand; 1996; 88():333-5. PubMed ID: 9119159
    [No Abstract]   [Full Text] [Related]  

  • 20. Adventitious agents from animal-derived raw materials--a method of risk assessment.
    Foster LG
    Dev Biol Stand; 1996; 88():283-90. PubMed ID: 9119152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.